Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
PhoreMost Enters Multi-Project Drug Target Discovery Collaboration with Roche
Details : Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 09, 2022
PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies
Details : PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 11, 2020
Reset All
